By Emmanuel Abara Benson / 14 January 2026
AstraZeneca is set to acquire Boston-based artificial intelligence firm Modella AI in a strategic move to deepen its use of AI across oncology research and drug development.
The deal brings Modella’s data, AI models and talent directly into AstraZeneca’s global research organisation, reflecting a shift from external partnerships to in-house capability for regulated drug research. The financial terms of the deal were not readily disclosed.
Modella AI specialises in advanced computational analysis of biomedical data, including digital pathology. Its foundation models and AI agents will be integrated into AstraZeneca’s oncology R&D efforts, with an initial focus on clinical development and biomarker discovery aimed at improving trial design and patient selection.
AstraZeneca Chief Financial Officer Aradhana Sarin, while speaking recently at the J.P. Morgan Healthcare Conference, said bringing Modella’s tools and expertise in-house will strengthen the company’s quantitative pathology and biomarker research capabilities, helping shorten the time between research insights and actionable clinical decisions.
Meanwhile, Modella AI’s chief commercial officer Gabi Raia emphasised that the acquisition will allow the company’s AI tools to be deployed across AstraZeneca’s global oncology trials, potentially accelerating innovation and decision-making in cancer drug development.
The acquisition builds on an earlier collaboration between the two companies that served as a “test drive” of Modella’s technologies within AstraZeneca’s research environment. AstraZeneca’s move signals a broader industry trend in which major pharmaceutical firms are seeking greater control over AI development and deployment by embedding tools and talent internally rather than relying solely on external vendors.
The announcement comes as the pharmaceutical sector continues to embrace AI, from partnerships to large-scale collaborations, towards tackling the increasing complexity and data intensity of modern drug discovery and development. AstraZeneca remains on track with its strategic plans for innovation and growth heading toward its 2030 revenue goals.
